Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

被引：2

作者：

Mesa, Ruben A. ^{[1
]}

Hoffman, Ronald ^{[2
]}

Kosiorek, Heidi E. ^{[3
]}

Prchal, Josef T. ^{[4
]}

Harrison, Claire N. ^{[5
]}

McMullin, Mary Frances ^{[6
]}

Yacoub, Abdulraheem ^{[7
]}

Rambaldi, Alessandro ^{[8
]}

Berenzon, Dmitriy ^{[9
]}

Vannucchi, Alessandro M. ^{[10
]}

Ewing, Joanne C. ^{[11
]}

O'Connell, Casey L. ^{[12
]}

Kiladjian, Jean-Jacques ^{[13
,14
]}

Mead, Adam ^{[15
]}

Winton, Elliott F. ^{[16
]}

Leibowitz, David S. ^{[17
]}

De Stefano, Valerio ^{[18
]}

Arcasoy, Murat O. ^{[19
]}

Kessler, Craig M. ^{[20
]}

Catchatorian, Rosalind ^{[21
]}

Rondelli, Damiano ^{[22
]}

Silver, Richard T. ^{[23
]}

Ritchie, Ellen K. ^{[24
]}

Nagler, Arnon ^{[25
]}

Kremyanskaya, Marina ^{[26
]}

Schlenk, Richard F. ^{[27
]}

Weinberg, Rona Singer ^{[28
]}

Salama, Mohamed E. ^{[29
]}

Tognoni, Gianni ^{[30
]}

Prosperini, Giuseppe ^{[30
]}

Di Lelio, Alessandra ^{[30
]}

Serone, Eliseo ^{[30
]}

Marfisi, Lorenzo ^{[30
]}

Orellana, Alicia ^{[31
]}

Barbui, Tiziano ^{[32
]}

Dueck, Amylou C. ^{[3
]}

Mascarenhas, John O. ^{[33
]}

机构：

[1] Mayo Clin, Scottsdale, AZ USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA

[3] Mayo Clin Canc Ctr, Phoenix, AZ USA

[4] Univ Utah, Div Hematol, Salt Lake City, UT 84112 USA

[5] Guys & St Thomas NHS Fdn Trust, London, England

[6] Queens Univ Belfast, Belfast, Antrim, North Ireland

[7] Univ Kansas, Med Hosp, Westwood, KS USA

[8] Univ Milan, ASST Papa Giovanni XXIII, Hematol & Bone Marrow Transplant Unit, Bergamo, Italy

[9] Wake Forest Sch Med, Comprehens Canc Ctr, Winston Salem, NC USA

[10] Univ Florence, Dept Expt & Clin Med, Florence, Italy

[11] Heart f England NHS Fdn Trust, Birmingham, W Midlands, England

[12] Univ Southern Calif, Norris Comprehens Canc Ctr, Jane Anne Nohl Div Hematol, Los Angeles, CA USA

[13] Hop St Louis, Paris, France

[14] Paris Diderot Univ, Paris, France

[15] Univ Oxford, MRC Mol Haematol Unit, Weatherall Inst Mol Med, Oxford, England

[16] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30303 USA

[17] Palo Alto Med Fdn, Palo Alto, CA USA

[18] Catholic Univ, Hematol, Rome, Italy

[19] Duke Univ Hlth Syst, Durham, NC USA

[20] Lombardi Canc Ctr, Washington, DC USA

[21] John H Stroger Hosp, Chicago, IL USA

[22] Univ Illinois, Div Hematol Oncol, Chicago, IL 60607 USA

[23] Weill Cornell Med, Dept Hematol Med Oncol, New York, NY USA

[24] Weill Cornell Med coll, New York, NY USA

[25] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplant, Ramat Gan, Israel

[26] Icahn Sch Med Mt Sinai, Myeloproliferative Res Consortium, Myeloproliferative Program, Tisch Canc Inst, New York, NY USA

[27] Univ Ulm, Dept Internal Med 3, Ulm, Germany

[28] NY Blood Ctr, White Plains, NY USA

[29] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA

[30] Ist Ric Farmacol Mario Negri, Milan, Italy

[31] Icahn Sch Med Mt Sinai, New York, NY USA

[32] Res Fdn FROM Hosp Papa Giovanni XXIII, Bergamo, Italy

[33] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4271.4271

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4271

引用

页数：6

共 9 条

[1] Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
Mesa, Ruben A.
Kosiorek, Heidi E.
Mascarenhas, John
Prchal, Josef T.
Rambaldi, Alessandro
Berenzon, Dmitriy
Yacoub, Abdulraheem
Harrison, Claire N.
McMullin, Mary Frances
Vannucchi, Alessandro M.
Ewing, Joanne
O'Connell, Casey L.
Kiladjian, Jean-Jacques
Mead, Adam J.
Winton, Elliott F.
Leibowitz, David S.
De Stefano, Valerio
Arcasoy, Murat O.
Kessler, Craig M.
Catchatourian, Rosalind
Rondelli, Damiano
Silver, Richard T.
Bacigalupo, Andrea
Nagler, Arnon
Kremyanskaya, Marina
Sandy, Lonette
Salama, Mohamed E.
Najfeld, Vesna
Tripodi, Joseph
Weinberg, Rona Singer
Rampal, Raajit K.
Hoffman, Ronald
Dueck, Amylou C.
BLOOD, 2018, 132
[2] Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
Mascarenhas, John O.
Prchal, Josef T.
Rambaldi, Alessandro
Mesa, Ruben A.
Berenzon, Dmitriy
Yacoub, Abdulraheem
Harrison, Claire N.
McMullin, Mary Frances
Vannucchi, Alessandro M.
Ewing, Joanne C.
O'Connell, Casey L.
Kiladjian, Jean-Jacques
Mead, Adam
Winton, Elliott F.
Leibowitz, David S.
De Stefano, Valerio
Arcasoy, Murat O.
Kessler, Craig M.
Catchatorian, Rosalind
Rondelli, Damiano
Silver, Richard T.
Ritchie, Ellen K.
Nagler, Arnon
Kremyanskaya, Marina
Schlenk, Richard F.
Weinberg, Rona Singer
Salama, Mohamed E.
Tognoni, Gianni
Prosperini, Giuseppe
Di Lelio, Alessandra
Serone, Eliseo
Marfisi, Lorenzo
Kleczko, Jill
Kosiorek, Heidi E.
Barbui, Tiziano
Dueck, Amylou C.
Hoffman, Ronald
BLOOD, 2016, 128 (22)
[3] Single-Arm Phase II Trial of Pegylated Interferon Alpha 2a in Patients with High-Risk Essential Thrombocythemia or Polycythemia Vera Resistant or Intolerant to Hydroxyurea: MPN Symptom Impact & Quality of Life Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Dueck, Amylou C.
Mascarenhas, John
Kosiorek, Heidi Elizabeth
Yacoub, Abdulraheem
Prchal, Josef T.
Berenzon, Dmitriy
Baer, Maria R.
Ritchie, Ellen K.
Silver, Richard T.
Kessler, Craig M.
Winton, Elliott F.
Finazzi, Maria Chiara
Rambaldi, Alessandro
Vannucchi, Alessandro M.
Leibowitz, David S.
Rondelli, Damiano
Arcasoy, Murat O.
Catchatourian, Rosalind
Vadakara, Joseph
Rosti, Vittorio
Hexner, Elizabeth
Kremyanskaya, Marina
Orellana, Alicia
Sandy, Lonette
Tripodi, Joseph
Najfeld, Vesna
Salama, Mohamed E.
Weinberg, Rona Singer
Rampal, Raajit K.
Hoffman, Ronald
Mesa, Ruben A.
BLOOD, 2017, 130
[4] Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials
Mazza, Gina L.
Mead-Harvey, Carolyn
Mascarenhas, John
Yacoub, Abdulraheem
Hoffman, Ronald
Kosiorek, Heidi E.
Prchal, Josef T.
Silver, Richard T.
Barbui, Tiziano
Dueck, Amylou C.
Mesa, Ruben
BLOOD, 2020, 136
[5] Results of the Myeloproliferative Neoplasms-Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea Therapy for the Treatment of High-Risk Polycythemia Vera and High-Risk Essential Thrombocythemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 6 - 8
[6] Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Mascarenhas, John
Kosiorek, Heidi E.
Prchal, Josef T.
Rambaldi, Alessandro
Berenzon, Dmitriy
Yacoub, Abdulraheem
Harrison, Claire N.
McMullin, Mary Frances
Vannucchi, Alessandro M.
Ewing, Joanne
O'Connell, Casey L.
Kiladjian, Jean-Jacques
Mead, Adam J.
Winton, Elliott F.
Leibowitz, David S.
De Stefano, Valerio
Arcasoy, Murat O.
Kessler, Craig M.
Catchatourian, Rosalind
Rondelli, Damiano
Silver, Richard T.
Bacigalupo, Andrea
Nagler, Arnon
Kremyanskaya, Marina
Sandy, Lonette
Salama, Mohamed E.
Najfeld, Vesna
Tripodi, Joseph
Weinberg, Rona Singer
Price, Leah
Goldberg, Judith D.
Rampal, Raajit K.
Mesa, Ruben A.
Dueck, Amylou C.
Hoffman, Ronald
BLOOD, 2018, 132
[7] Single-Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) Protocol 111 Global Phase II Trial
Yacoub, Abdulraheem
Mascarenhas, John
Kosiorek, Heidi Elizabeth
Prchal, Josef T.
Berenzon, Dmitriy
Baer, Maria R.
Ritchie, Ellen K.
Silver, Richard T.
Kessler, Craig M.
Winton, Elliott F.
Finazzi, Maria Chiara
Rambaldi, Alessandro
Vannucchi, Alessandro M.
Leibowitz, David S.
Rondelli, Damiano
Arcasoy, Murat O.
Catchatourian, Rosalind
Vadakara, Joseph
Rosti, Vittorio
Hexner, Elizabeth
Kremyanskaya, Marina
Orellana, Alicia
Sandy, Lonette
Tripodi, Joseph
Najfeld, Vesna
Salama, Mohamed E.
Weinberg, Rona Singer
Rampal, Raajit K.
Mesa, Ruben A.
Goldberg, Judith D.
Dueck, Amylou C.
Hoffman, Ronald
BLOOD, 2017, 130
[8] Single-Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High-Risk Polycythemia Vera or High-Risk Essential Thrombocythemia Who Are Either Hydroxyurea-Resistant or Intolerant: Final Results of the Myeloproliferative Disorders-Research Consortium Protocol 111 Global Phase II Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 12 - 14
[9] Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials
Mazza, Gina L.
Mead-Harvey, Carolyn
Mascarenhas, John
Yacoub, Abdulraheem
Kosiorek, Heidi E.
Hoffman, Ronald
Dueck, Amylou C.
Mesa, Ruben A.
LANCET HAEMATOLOGY, 2022, 9 (01): : E38 - E48

← 1 →